Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 20/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 17/20 | 0.59 |
| ▸ | PSMB9 | P28065 | 6/20 | 0.59 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052789 | 1.00 | PSMB8 (0.59) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL20821038 | 0.94 | PSMB8 (0.70) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL8100922 | 0.94 | PSMB8 (0.70) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL19316089 | 0.92 | PSMB5 (0.56) | PSMB8PSMB5PSMB9PSMB2PSMB1 | |
| SCHEMBL16119181 | 0.92 | PSMB5 (0.56) | PSMB8PSMB5PSMB9PSMB2PSMB1 | |
| SCHEMBL18327453 | 0.91 | PSMB8 (0.52) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL16118685 | 0.91 | PSMB8 (0.52) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL15568779 | 0.90 | CTSS (0.58) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL15594256 | 0.90 | CTSS (0.58) | PSMB8PSMB5PSMB9PSMB10PSMB2 | |
| SCHEMBL15568780 | 0.90 | CTSS (0.58) | PSMB8PSMB5PSMB9PSMB10PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | PSMB8 20/4885PSMB5 4/4885PSMB9 49/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | PSMB8 20/4885PSMB5 4/4885PSMB9 49/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | PSMB8 20/4885PSMB5 4/4885PSMB9 49/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | PSMB8 20/4885PSMB5 4/4885PSMB9 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.